Hey there! Big news from Palatin Technologies, Inc. They’ve got the green light from the FDA to kick off a Phase 2 clinical trial for a potential obesity treatment. They’re combining bremelanotide, which targets a specific receptor in the body, with tirzepatide, another drug already used for obesity. The trial, set to start later this year, will enroll around 60 obese patients across five sites in the U.S.
The goal? To see if combining these two drugs can help folks shed those extra pounds more effectively and safely. They’ll start by treating patients with tirzepatide alone for four weeks, then switch some of them to different treatment plans involving both drugs. Safety and weight loss effectiveness will be closely monitored throughout the study.
Palatin’s CEO, Carl Spana, is pretty pumped about this. He thinks the combo of these two drugs could be a game-changer in the fight against obesity. With the FDA giving them the nod to move forward, it looks like we’ll have some solid data on this potential treatment by the end of the year. Exciting stuff!
